Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 19.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 19.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Ariad Pharmaceuticals, Inc., Baxalta US Inc., Bristol-Myers Squibb, Celgene, Genentech, Inc., Gilead, Incyte Corporation, Infinity Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pharmacyclics LLC and Janssen Biotech, Inc., Seattle Genetics, Takeda Oncology, and TG Therapeutics, Inc.

20th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

20th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

International Congress on Hematologic Malignancies trifold
Click here to download brochure
March 18 - 20, 2016
Eden Roc Miami
4525 Collins Avenue
Miami Beach, FL 33140
Phone: 305-531-0000


Now in its 20th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is designed to facilitate clinician application of the wealth of emerging data in treating hematologic malignancies, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients.

New for this year! We have extended the Congress to a 3-day meeting. This speaks volumes to the tremendous amount of progress and wealth of new data in a variety of hematologic malignancies. This year’s program will focus on key clinical topics in the field, with a particular focus on leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, benign hematologic disorders, and mitigation and management of adverse events. Patient cases will be presented and discussed with the audience in a manner designed to engage their participation and in the context of methods to practically apply pivotal trial data to everyday practice. Additionally, the well-known and highly interactive Medical Crossfire® discussion panels will allow for exploration of some of the most challenging topics for which there may be many potential approaches to care.

This highly practical and interactive forum will provide a unique opportunity for oncologists and other healthcare professionals to learn from and interact with leading expert national faculty in order to increase their clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.

Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Describe current and evolving genomic and molecular biomarkers that can be used to stratify risk and inform clinical decision-making in the management of hematologic malignancies
  • Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms and can be applied to personalize care and optimize outcomes
  • Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of hematologic malignancies so that treatment outcomes can be maximized
  • Evaluate recent clinical trial findings concerning novel compounds or strategies to manage hematologic malignancies
  • Consider the therapeutic implications of emerging data on evolving treatment paradigms for patients with hematologic tumors


Andre Goy, MD, MS
Chairman and Director, Chief of Lymphoma
Director, Clinical and Translational Cancer Research
John Theurer Cancer Center at Hackensack University Medical Center
Professor of Medicine, Georgetown University
Hackensack, NJ

Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By